AtriCure, Inc.
35.44-1.01 (-2.77%)
Oct 29, 4:00:02 PM EDT · NasdaqGM · ATRC · USD
Key Stats
Market Cap
1.76BP/E (TTM)
-Basic EPS (TTM)
-0.77Dividend Yield
0%Recent Filings
8-K
10-Q
Q2 FY2025 results
AtriCure posted Q2 revenue of $136.1M, up 17.1% y/y from $116.3M, with appendage management and pain management driving gains while minimally invasive ablation dipped 33.7%. Gross margin held steady at 74.5%, but operating loss narrowed to $6.2M from $7.2M as revenue momentum outpaced SG&A growth. YTD revenue climbed 15.4% to $259.8M, trimming net loss to $12.9M or $0.27 per diluted share on 47,557 weighted shares, consistent with anti-dilution from 2,930 options. Cash at $117.8M supports $61.9M debt under a $125M ABL facility maturing 2027, with $61.9M availability; operating cash flow turned positive at $10.6M YTD, yielding $5.7M free cash flow (derived). The $5M IPR&D milestone for pulsed field ablation tech bolsters innovation. Litigation over SentreHEART milestones poses a contingent risk.
8-K
Q2 revenue jumps 17.1%
AtriCure reported Q2 2025 revenue of $136.1 million, up 17.1% year-over-year, fueled by strong U.S. growth in appendage management and pain products, while international sales surged 23.3%. Net loss narrowed to $6.2 million, with adjusted EBITDA hitting $15.4 million. The company raised its full-year revenue outlook to $527–$533 million and completed enrollment in the pivotal LeAAPS trial. Momentum builds, yet R&D costs rose sharply.
8-K
Stock plan shares increased
AtriCure's stockholders approved an amendment to the 2023 Stock Incentive Plan at the May 19, 2025 annual meeting, boosting available shares from 2.8 million to 4.5 million to attract and retain talent while aligning interests with shareholders. All nine director nominees won election, Deloitte's auditor role was ratified, and exec pay drew advisory approval—yet the vote on pay frequency favored yearly checks. This bolsters equity incentives amid talent wars.
10-Q
Q1 FY2025 results
AtriCure posted solid Q1 FY2025 results, with revenue climbing 13.6% year-over-year to $123.6M, fueled by 17.3% growth in appendage management and 35.6% in pain management, while U.S. sales rose 12.1% and international jumped 20.8%. Gross margin edged up to 74.9%, but operating expenses grew 6.9% to $98.6M, narrowing the operating loss to $6.0M from $10.9M last year. Net loss improved to $6.7M or $0.14 per diluted share, confirmed against 47,393 weighted shares with 3,008 anti-dilutive options excluded. Cash dipped to $99.9M amid $11.0M operating outflow, offset by $61.9M debt and $61.9M revolver availability maturing 2027 at 6.92%. Revenue thrives on product launches. Yet new competitors loom large.
IPO
Website
Employees
Sector
Industry
AHICF
Asahi Intec Co., Ltd.
15.08-1.06
ANGO
AngioDynamics, Inc.
12.12-0.17
AORT
Artivion, Inc.
44.99-0.27
ATR
AptarGroup, Inc.
124.31-3.79
AVTR
Avantor, Inc.
11.58-3.50
ECIA
Encision, Inc.
0.35+0.12
ICCM
IceCure Medical Ltd.
0.75-0.02
ICUI
ICU Medical, Inc.
117.67-2.44
PLSE
Pulse Biosciences, Inc
17.11-0.24
VTAK
Catheter Precision, Inc.
2.44-0.12